Brumme ZL - Search Results

1

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response.

Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Brumme ZL, et al. AIDS. 2003 Jan 24;17(2):201-8. doi: 10.1097/00002030-200301240-00010. AIDS. 2003. PMID: 12545080

2

Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Côté HC, Brumme ZL, Harrigan PR. Côté HC, et al. Among authors: brumme zl. J Virol. 2001 Jan;75(2):589-94. doi: 10.1128/JVI.75.2.589-594.2001. J Virol. 2001. PMID: 11134271 Free PMC article.

3

CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response.

Brumme ZL, Chan KJ, Dong W, Hogg R, O'Shaughnessy MV, Montaner JS, Harrigan PR. Brumme ZL, et al. AIDS. 2001 Nov 23;15(17):2259-66. doi: 10.1097/00002030-200111230-00007. AIDS. 2001. PMID: 11698699

4

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV, Montaner JS. Côté HC, et al. Among authors: brumme zl. N Engl J Med. 2002 Mar 14;346(11):811-20. doi: 10.1056/NEJMoa012035. N Engl J Med. 2002. PMID: 11893792 Free article.

5

Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.

Harrigan PR, Miller MD, McKenna P, Brumme ZL, Larder BA. Harrigan PR, et al. Among authors: brumme zl. Antimicrob Agents Chemother. 2002 Apr;46(4):1067-72. doi: 10.1128/AAC.46.4.1067-1072.2002. Antimicrob Agents Chemother. 2002. PMID: 11897591 Free PMC article.

6

A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.

Harrigan PR, Salim M, Stammers DK, Wynhoven B, Brumme ZL, McKenna P, Larder B, Kemp SD. Harrigan PR, et al. Among authors: brumme zl. J Virol. 2002 Jul;76(13):6836-40. doi: 10.1128/jvi.76.13.6836-6840.2002. J Virol. 2002. PMID: 12050397 Free PMC article.

7

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.

Brumme ZL, Chan KJ, Dong WW, Mo T, Wynhoven B, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Brumme ZL, et al. AIDS. 2002 Sep 27;16(14):1929-33. doi: 10.1097/00002030-200209270-00010. AIDS. 2002. PMID: 12351953

8

Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.

Brumme ZL, Chan KJ, Dong WW, Wynhoven B, Mo T, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Brumme ZL, et al. Antivir Ther. 2003 Apr;8(2):91-6. Antivir Ther. 2003. PMID: 12741620

9

Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury.

Davani EY, Brumme Z, Singhera GK, Côté HC, Harrigan PR, Dorscheid DR. Davani EY, et al. Crit Care. 2003 Dec;7(6):R176-83. doi: 10.1186/cc2375. Epub 2003 Oct 10. Crit Care. 2003. PMID: 14624693 Free PMC article.

10

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.

Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS. Harrigan PR, et al. Among authors: brumme zl. Antivir Ther. 2003 Oct;8(5):395-402. Antivir Ther. 2003. PMID: 14640386 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

224 results

Search Page

Filters